ArticleScientific reports2026
Partial responders to intravenous corticosteroids at day 3 benefit from continued therapy in acute severe ulcerative colitis.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In acute severe ulcerative colitis (ASUC), early response patterns to intravenous corticosteroids (IVCS) during the first week may shape subsequent disease course. Characterizing these trajectories is crucial for guiding timely therapy and improving patient outcomes. We evaluated response patterns to IVCS in hospitalized patients with ASUC. Clinical response was categorized as complete response (CR), partial response (PR), or non-response (NR) on days 3, 5, and 7. Patients were followed up to day 90 for need for rescue therapy (RT), post-discharge escalation of therapy (EOT), and mortality. Seventy-nine patients were analyzed. By day 3, 12 (15%) achieved CR, 34 (43%) PR, and 33 (42%) NR. Among the 67 patients with PR or NR on day 3, 9 (13.4%) achieved CR by day 5 and 22 (32.8%) more by day 7. On day 7, CR, PR, and NR were observed in 42 (53%), 17 (21%), and 20 (25%) patients, respectively. Patients with CR on day 3 had a lower, but not statistically significant, likelihood of needing RT + EOT by day 90 compared to NR (29% vs. 47%; p = 0.15). However, by day 5, patients with CR or PR had significantly lower day 90 RT + EOT needs compared to NR (26% vs. 54%, p = 0.02; 23% vs. 54%, p = 0.03). By day 7, the day 90 probability of RT + EOT was higher in PR (45%) and NR (63%) versus CR (16%) (p = 0.001 and < 0.0001, respectively). Only a small proportion of patients with ASUC show CR at day 3; most are partial responders. Partial responders to IVCS at day 3 frequently achieve CR by day 5-7, and have relatively favorable short term disease course, highlighting the prognostic value of early response stratification.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.